Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi

BACKGROUND: In this phase 2 randomised placebo-controlled clinical trial in patients with COVID-19, we hypothesised that blocking mineralocorticoid receptors using a combination of dexamethasone to suppress cortisol secretion and spironolactone is safe and may reduce illness severity. METHODS: Hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wadhwa, Bharti, Malhotra, Vikas, Kerai, Sukhyanti, Husain, Farah, Pandey, Nalini Bala, Saxena, Kirti N., Singh, Vinay, Quinn, Tom M., Li, Feng, Gaughan, Erin, Shankar-Hari, Manu, Mills, Bethany, Antonelli, Jean, Bruce, Annya, Finlayson, Keith, Moore, Anne, Dhaliwal, Kevin, Edwards, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184093/
https://www.ncbi.nlm.nih.gov/pubmed/37189034
http://dx.doi.org/10.1186/s12879-023-08286-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184093/
https://www.ncbi.nlm.nih.gov/pubmed/37189034
http://dx.doi.org/10.1186/s12879-023-08286-w

Ejemplares similares